Michigan GOP Bill Would Redirect $50 Million in Opioid Settlement Funds to Ibogaine Research for Veterans

In an unexpected convergence of conservative politics and psychedelic medicine, a Michigan Republican lawmaker has proposed using $50 million in opioid settlement funds to finance clinical trials of ibogaine—a powerful psychedelic compound showing remarkable promise in treating addiction and trauma among veterans.

State Representative Jaime Green of Richmond, a former U.S. Navy cryptologist, introduced House Bill 6020 on Tuesday, calling on Michigan to leverage its substantial opioid settlement resources to explore what she describes as potentially transformative treatment for service members carrying "invisible wounds of service." The bill would establish a state-funded research consortium to investigate ibogaine's therapeutic potential for post-traumatic stress disorder, traumatic brain injury, depression, and substance use disorders.

From Opioid Crisis to Psychedelic Research

The proposed legislation represents a novel approach to deploying the billions of dollars states have received from pharmaceutical litigation. Michigan's Opioid Healing and Recovery Fund, which holds approximately $1.8 billion from national opioid settlements, has traditionally supported conventional treatment expansion, naloxone distribution, and recovery housing. Green's proposal would redirect a portion of these resources toward investigating a Schedule I controlled substance that remains illegal for any use under federal law.

"For many veterans, the battle does not end when they come home," Green testified before the House Families and Veterans Committee. "Too many carry the invisible wounds of service—post-traumatic stress, traumatic brain injury, depression, chronic pain, substance abuse disorder. In some cases, opioid dependence begins with an injury, a prescription to manage the pain, or the trauma. Michigan has a responsibility to stand with the men and women who serve this country."

The legislation would create an ibogaine research fund administered by the Michigan Department of Health and Human Services, with authority to establish partnerships with drug manufacturers, health facilities, and research universities. The University of Michigan's medical research infrastructure features prominently in Green's vision for the program.

The Science Behind Ibogaine

Ibogaine, derived from the root bark of the African iboga shrub, has generated significant scientific interest despite—or perhaps because of—its complex risk profile. The compound produces profound psychedelic experiences lasting 12 to 24 hours, during which patients often report revisiting traumatic memories and gaining psychological insights. Unlike conventional antidepressants that require weeks to show effects, ibogaine appears to produce rapid, sustained improvements in mood and substance cravings.

A landmark 2024 study from Stanford Medicine demonstrated significant reductions in PTSD, depression, and anxiety symptoms among special forces veterans one month after ibogaine treatment. The research, co-authored by Stanford clinical assistant professor Ian Kratter, found that participants with traumatic brain injuries showed measurable cognitive improvements alongside psychological benefits. These findings have fueled growing advocacy for federal research into psychedelic-assisted therapies for veteran populations.

However, ibogaine's therapeutic potential comes with substantial cardiovascular risks. The compound can trigger dangerous cardiac arrhythmias, requiring continuous medical monitoring throughout the treatment experience. This safety profile has limited research to carefully supervised clinical settings and has prevented widespread adoption despite anecdotal reports of dramatic addiction interruption.

Political Crosscurrents

Green's proposal arrives at a moment of unusual bipartisan alignment around psychedelic medicine, even as broader drug policy remains deeply polarized. President Trump's recent executive order allocating $50 million for state-level psychedelic research has created federal tailwinds for precisely this type of initiative. The order directs the Attorney General to review and potentially reschedule psychedelic substances that receive FDA approval, potentially clearing a pathway for clinical use.

Michigan would join a growing cohort of states exploring psychedelic research through legislative channels. Louisiana lawmakers recently passed a bill creating a psychedelic therapy pilot program funded by opioid settlement dollars, targeting similar conditions with psilocybin, MDMA, and ibogaine. Ohio's Ibogaine Treatment Study Committee convened its first meeting last month, while Texas and Mississippi have established state-funded psychedelic research programs focused on veteran mental health.

The political calculus surrounding Green's bill remains complex. While veteran advocacy has proven effective at building bipartisan coalitions for psychedelic research, the specific mechanism—diverting opioid settlement funds—may generate resistance from lawmakers who view those resources as committed to conventional addiction treatment infrastructure. Green emphasized that her proposal would not legalize ibogaine for recreational use or impact existing settlement-funded projects.

The Veteran Suicide Crisis

The urgency underlying Green's legislation reflects a devastating reality: more than 6,000 American veterans die by suicide annually, with rates exceeding combat deaths in recent years. For many service members, conventional psychiatric medications and therapy have provided inadequate relief, driving some to seek unregulated ibogaine treatment at clinics in Mexico and other countries where the substance is legally available.

This medical tourism carries substantial risks. Unregulated clinics may lack adequate cardiac monitoring or medical expertise to manage complications. Veterans returning from such treatments report transformative experiences but also dangerous encounters with providers operating outside any regulatory framework. Establishing domestic clinical trials would allow veterans to access potentially life-saving treatment under rigorous safety protocols.

The connection between opioid dependence and veteran trauma adds another dimension to Green's proposal. Many veterans develop substance use disorders following service-related injuries treated with prescription opioids, creating a pathway from legitimate medical care to addiction. Ibogaine's apparent ability to simultaneously address trauma symptoms and substance cravings could offer integrated treatment for this population.

Research Infrastructure and Challenges

If enacted, House Bill 6020 would require Michigan to navigate complex regulatory terrain. As a Schedule I substance, ibogaine research requires approval from the Drug Enforcement Administration, FDA investigational new drug applications, and institutional review board oversight. The state would need to establish specialized clinical facilities capable of continuous cardiac monitoring throughout the extended treatment duration.

The proposed consortium model—bringing together academic medical centers, pharmaceutical partners, and healthcare facilities—mirrors successful approaches used in other complex clinical trials. The University of Michigan's established research infrastructure would likely serve as an anchor institution, though the legislation contemplates multi-site studies that could generate statistically robust data.

Funding represents another challenge. While the $50 million appropriation would provide substantial initial resources, comprehensive clinical trials for multiple indications could require significantly greater investment. The bill's proponents will need to demonstrate that this allocation represents a worthwhile investment of opioid settlement dollars that might otherwise fund immediate treatment access expansion.

Looking Forward

The House Families and Veterans Committee took testimony on House Bill 6020 without voting, suggesting the proposal remains in early stages of legislative consideration. Committee members heard from ibogaine researchers, veteran advocates, and medical professionals describing both the compound's therapeutic potential and its safety challenges.

For Michigan's substantial veteran population, the legislation represents a potential pathway to treatments that conventional medicine has failed to provide. For the broader addiction treatment field, it signals growing political willingness to explore psychedelic interventions that were dismissed as fringe science just years ago.

The bill also raises fundamental questions about how states should deploy opioid settlement funds. With billions of dollars flowing to jurisdictions nationwide, Michigan's experiment with psychedelic research funding could establish precedent for other states seeking innovative approaches to addiction and trauma treatment. Whether that precedent proves influential may depend on the clinical results that House Bill 6020 seeks to generate.

As the opioid crisis continues evolving—with overdose deaths declining nationally but remaining catastrophically high—treatment innovation has taken on renewed urgency. Ibogaine remains a compound of substantial promise and substantial risk, precisely the type of therapeutic candidate that rigorous clinical trials are designed to evaluate. Green's legislation would provide Michigan veterans access to that evaluation process without requiring them to cross international borders or navigate unregulated medical markets.